key: cord-0772676-4g7kpo4b authors: Alharthy, Abdulrahman; Aletreby, Waleed; Faqihi, Fahad; Balhamar, Abdullah; Alaklobi, Feisal; Alanezi, Khaled; Jaganathan, Parameaswari; Tamim, Hani; Alqahtani, Saleh A; Karakitsos, Dimitrios; Memish, Ziad A title: Clinical Characteristics and Predictors of 28-Day Mortality in 352 Critically Ill Patients with COVID-19: A Retrospective Study date: 2021-03-03 journal: J Epidemiol Glob Health DOI: 10.2991/jegh.k.200928.001 sha: 252f9a8bce5e37f7f4ca20166fde73bbde863e55 doc_id: 772676 cord_uid: 4g7kpo4b Background: Since the first COVID-19 patient in Saudi Arabia (March, 2020) more than 338,539 cases and approximately 4996 dead were reported. We present the main characteristics and outcomes of critically ill COVID-19 patients that were admitted in the largest Ministry of Health Intensive Care Unit (ICU) in Saudi Arabia. Methods: This retrospective study, analyzed routine epidemiologic, clinical, and laboratory data of COVID-19 critically ill patients in King Saud Medical City (KSMC), Riyadh, Saudi Arabia, between March 20, 2020 and May 31, 2020. Severe acute respiratory syndrome coronavirus-2 infection was confirmed by real-time reverse transcriptase polymerase chain reaction assays performed on nasopharyngeal swabs in all enrolled cases. Outcome measures such as 28-days mortality, duration of mechanical ventilation, and ICU length of stay were analyzed. Results: Three-hundred-and-fifty-two critically ill COVID-19 patients were included in the study. Patients had a mean age of 50.63 ± 13.3 years, 87.2% were males, and 49.4% were active smokers. Upon ICU admission, 56.8% of patients were mechanically ventilated with peripheral oxygen saturation/fraction of inspired oxygen (SpO(2)/FiO(2)) ratio of 158 ± 32. No co-infections with other endemic viruses were observed. Duration of mechanical ventilation was 16 (IQR: 8–28) days; ICU length of stay was 18 (IQR: 9–29) days, and 28-day mortality was 32.1%. Multivariate regression analysis showed that old age [Odds Ratio (OR): 1.15, 95% Confidence Intervals (CI): 1.03–1.21], active smoking [OR: 3, 95% CI: 2.51–3.66], pulmonary embolism [OR: 2.91, 95% CI: 2.65–3.36), decreased SpO(2)/FiO(2) ratio [OR: 0.94, 95% CI: 0.91–0.97], and increased lactate [OR: 3.9, 95% CI: 2.4–4.9], and d-dimers [OR: 2.54, 95% CI: 1.57–3.12] were mortality predictors. Conclusion: Old age, active smoking, pulmonary embolism, decreased SpO(2)/FiO(2) ratio, and increased lactate and d-dimers were predictors of 28-day mortality in critically ill COVID-19 patients. However, only a few studies were focused on the analysis of risk factors affecting morbidity and mortality in critically ill COVID-19 patients. Herein, we present a retrospective analysis of the clinical characteristics and the risk factors, which influenced 28-day mortality post-ICU admission, in three hundred and fifty two critically ill COVID-19 patients. We retrospectively analyzed critically ill patients with COVID-19 admitted to our COVID-19 designated ICU from March 20, 2020 to May 31, 2020 . SARS-CoV-2 infection was confirmed by Real-Time-Polymerase-Chain-Reaction (RT-PCR) assays, performed on nasopharyngeal swabs, using QuantiNova Probe RT-PCR kit (Qiagen, GmbH, Germany) in a Light-Cycler 480 real-time PCR system (Roche, Basel, Switzerland) as described in detail elsewhere [40, 41] . Inclusion criteria were: (1) Adult > 18 years old, and (2) ICU admission. Exclusion criteria were: (1) Negative RT-PCR result for COVID-19 in two consecutive samples taken 48 h apart, (2) patients that were transferred to other COVID-19 designated hospitals based on our Ministry of Health (MOH) surge plan, and (3) Health care workers with nosocomial acquisition of SARS-CoV-2 infection. The primary end-point was to investigate risk factors affecting 28-day mortality post-ICU admission. Usual outcome measures such as duration of mechanical ventilation, ICU and hospital length of stay were integrated in the analysis. The study was conducted according to the principles outlined in the Declaration of Helsinki, and was approved by our Institutional Review Board. COVID-19 patient data recorded in health care records included routine demographic data, medical history, epidemiological exposure, comorbidities, symptoms, signs, laboratory results, coinfections and bacterial cultures results, chest X-rays and Computed Tomographic (CT) scans, applied therapies (i.e., antiviral therapy, corticosteroids, rescue invasive therapies, supportive ICU care), in-hospital complications, and clinical outcomes, were retrospectively analyzed. Pulmonary Embolism (PE) was confirmed by chest computed tomography angiography. Acute Kidney Injury (AKI) was defined as per the "risk", "injury", and "failure" criteria [42] ; while Continuous Renal Replacement Therapy (CRRT) was performed as per the kidney disease improving global outcomes 2019 guidelines when deemed to be necessary (i.e., anuria, metabolic acidosis, hyperkalemia) [43] . Interventional extracorporeal rescue therapies were performed according to pertinent ICU protocols. For example, Extracorporeal Membrane Oxygenation (ECMO) was applied on patients with refractory hypoxemia [fraction of peripheral oxygen saturation to inspired oxygen saturation (PaO 2 / FiO 2 ratio) < 80 for more than 6 h] based on available resources and practice recommendations [44] . Moreover, several critically ill patients with life-threatening COVID-19 and associated cytokine release syndrome were enrolled in our study regarding the administration of rescue Therapeutic Plasma Exchange (TPE) [45, 46] . Upon ICU admission, we administered to all critically ill COVID-19 patients baseline therapy integrating ARDS-net and prone positioning ventilation, empiric antiviral treatment with ribavirin, and interferon beta-1b, as well as antibiotics, corticosteroids, anticoagulation, and other ICU supportive care as per individual clinical case scenario, and according to the Saudi MOH therapeutic protocol [47] . Admission Sequential Organ Function Assessment (SOFA) score, ICU Length of Stay (LOS), hospital LOS, clinical and paraclinical data were registered in all cases. All data were stored in electronic format and retrospectively analyzed. Categorical variables are presented as absolute numbers or percentages. Continuous parameters are expressed as mean values ± Standard Deviation (SD) or median values with Interquartile Range (IQR) depending on their distribution. Differences of the studied parameters between survivors and non-survivors COVID-19 patients were evaluated by Wilcoxon Rank sum test for non-parametric data, and the student's t-test for parametric data as appropriate. Logistic regression was used for each studied parameter over the binary outcome (survival/death) in univariate analysis. The significant predictors for 28-day mortality (p < 0.1) were used for multivariate regression modeling integrating Odds Ratio (OR) with 95% Confidence Intervals (CI). The forward stepwise method was adopted and tested for its goodness of fit by Hosmer-Lemeshow test. Survival analysis was visually presented by Kaplan-Meier curves, while the log-rank test was used to confirm the significance of probability trends for different age groups of COVID-19 patients. All tests were two tailed and considered significant when p-value <0.05. All data were analyzed using Stata/IC The study flowchart is illustrated in Figure 1 . Out of 436 critically ill patients with COVID-19, 352 were included in the final analysis. Eighty four patients were excluded due to transfer to other COVID-19 designated hospitals. Of the 352 mechanically ventilated COVID-19 patients that were retrospectively analyzed, Non-survivors were more frequently active smokers, and had higher SOFA scores on ICU admission, increased lactate, and d-dimers, and decreased lymphocyte counts and saturation of peripheral oxygen/fraction of inspired oxygen (SpO 2 /FiO 2 ) ratio compared to survivors (Table 1) . During ICU hospitalization, cerebrovascular accidents, which were linked to COVID-19 status, occurred less frequently in survivors compared to non-survivors (2% vs. 7%, p < 0.05, respectively). The prevalence of PE was higher in non-survivors compared to survivors (15% vs. 7%, p < 0.05). AKI developed equally to survivors and non-survivors, while no significant difference was observed in the rate of applied CRRT or other invasive therapies between survivors and non-survivors. However, the putative effect of interventional therapies on survival was not analyzed as this was not an end-point of this study. In the univariate logistic regression analysis, eight variables had significant effect on 28-day mortality. These variables were: age, ICU length of stay, SpO 2 /FiO 2 ratio, white blood cells and lymphocytes counts, d-dimers and lactate levels, presence of PE, and active smoker status; hence, these parameters were also included in the multivariate regression analysis. These models are both illustrated in Table 2 . Hosmer-Lemeshow test confirmed that the model was well fit with a high sensitivity 91.5% and specificity 95.2% in predicting mortality risk factors along with a positive predictive value of 89.8%, and negative predictive value of 96%, respectively. Five parameters emerged as significant predictors of 28-day mortality in this cohort of COVID-19 critically ill patients: old age, active smoker status, presence of PE, increased serum lactate and d-dimers (Table 2) . Kaplan-Meier curves for 28-day mortality that were observed in different age groups of this cohort of critically ill COVID-19 patients are illustrated in Figure 2 . The mean survival time post-ICU admission in different age groups is also presented in Table 3 . The significance of survival trends that were observed in different age groups was confirmed by Mantel-Cox log-rank test (p = 0.005). Hence, the worst survival rates were observed in the group 51-60 years of age followed by the group 41-50 years of age ( Figure 2 and Table 3 ). The main findings of this retrospective study can be summarized as follows. We found that old age, presence of PE, and increased lactate and d-dimers were associated with poor prognosis in mechanically ventilated patients with COVID-19, which is in accordance with previous reports . An increased prevalence of thromboembolic disease was reported in critically ill COVID-19 patients and is a poor prognostic marker [5] [6] [7] 12, 48, 49] . Accordingly, increased levels of d-dimers were associated with poor prognosis in critically ill COVID-19 patients [24] . Hypercoagulability, vascular dysfunction, and hyperinflammation were suggested underlying mechanisms promoting thromboembolic disease in severe COVID-19 [5] [6] [7] 12, [48] [49] [50] . SARS-CoV-2 can bind to the ACE-2 receptors that are expressed on type II pneumocytes and vascular endothelial cells in the lung, and thus cause direct injury to the pulmonary vasculature [50] . The development of PE along with the lung parenchymal inflammation could signify a "dual-hit" underlying mechanism, which in turn may result in refractory ARDS [51] . The presence of comorbidities and old age are poor prognostic indicators in hospitalized COVID-19 patients [4, [9] [10] [11] [16] [17] [18] [19] 31, 32, [34] [35] [36] [37] [38] [39] . We found higher mortality rates in elderly patients; however, middle aged patients (41-50 years old) had also relatively high rates [4] . The mean age of our critically ill COVID-19 patients was younger compared to other studies [1] [2] [3] [4] 10, [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] . This may be partially explained by the fact that the mean age of the general population in our country is relatively lower (≥65 years is <3%); compared to Asian, European, and American countries that were affected by the pandemic. Another possible explanation is that SARS-CoV-2 can also affect younger individuals with detrimental results [4, 10, [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] . These patients may present with severe extra-pulmonary manifestations such as brain infarctions [52] . In our study, although the incidence of stroke was higher in nonsurvivors, these were mainly elderly patients with other comorbidities. Moreover, we could not perform a detailed analysis of the neurological findings due to incomplete brain imaging information that were available during the study period. Data from the UK and North America showed that black patients with COVID-19 had increased odds of death [53, 54] . In our study, most patients were of Asian and Middle Eastern ethnic origin, and the vast majority was of non-Saudi nationality. We found that the majority of patients had ABO blood group type O+ (47%), but no correlation of ABO blood group type with mortality existed as it was previously suggested [55] [56] [57] . The incidence of hospital acquired bacterial infections, which was observed in this retrospective series, was comparable to other reports [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] . We did not find any co-infections with other endemic viruses such as MERS-CoV, which is in accordance with a previous Saudi Arabia based study [58] . Notwithstanding, the putative benefit from past exposure to MERS-CoV cannot be definitely excluded since a 50% genomic similarity between these two beta-coronaviruses exists. Also, we found that active smoking was a predictor of mortality in critically ill COVID-19 patients. Anecdotal reports advocated that smoking was partially protective for COVID-19 in the beginning of the pandemic [59] [60] [61] . However, our results further confirmed recent studies that smokers and patients with chronic obstructive pulmonary disease have increased odds of poor outcome when infected by SARS-CoV-2 [16, 17, 28, 29, 62, 63] . This study has inherent limitations mainly due to its retrospective, single-center design. Also, the effect of applied interventional extracorporeal therapies such as ECMO or TPE on survival was not studied as this was not an end-point of the study. The latter was focused mainly on analyzing routine epidemiologic and clinical data of critically ill COVID-19 patients. In contrast to previous reports, we did not exclude critically ill patients that expired within the first 48 h after ICU admission as we wished to include the effect of fulminant COVID-19 and/or the occurrence of severe post-admission complications in our analysis [9, 39] . Also, other clinical and paraclinical data such as mechanical ventilation parameters, detailed laboratory and imaging data were not available in all cases, which prevented a more meaningful subgroup analysis. The 28-day post-ICU admission mortality rate was 32.1%, which is relatively lower compared to initial reports in mechanically ventilated COVID-19 patients from China, Europe, and the US [4, [9] [10] [11] 16, [37] [38] [39] . Notably, AKI that was previously identified as an independent predictor of mortality in critically ill COVID-19 patients did not emerge as a factor influencing mortality in our study [27] [28] [29] [30] [31] [32] [34] [35] [36] [37] [38] [39] . We are uncertain whether this might be explained by the prompt application of interventional therapies such as CRRT or it could be attributed to the clinical notion that COVID-19 may not necessarily result in AKI [33] . Despite the aforementioned limitations, we found that old age, decreased SpO 2 /FiO 2 ratio, and increased lactate, and d-dimers along with higher prevalence of PE, and active smoking were all poor prognostic factors in critically ill COVID-19 patients. Surely, different factors affecting mortality were identified based on the various studies' designs thus far. In that sense, more prospective studies are required to analyze all putative factors affecting mortality in critically ill patients with COVID-19. Given his role as Editor in Chief, Ziad Memish had no involvement in the peer-review of this article and has no access to any information regarding its peer-review. Full responsibility for the editorial process for this article was delegated to Dr. Shahul Ebrahim. All other authors have no conflicts of interest to disclose. AA contributed in idea, concept, proposal, data interpretation, manuscript writing, and final approval. WA contributed in idea, concept, proposal, data collection, data entry, data analysis, manuscript writing, and final approval. FF, AB, FA, KA, PJ and HT contributed in idea, concept, proposal, data collection, data analysis, manuscript writing, and final approval. SAA and DK contributed in data interpretation, manuscript writing, critical reviewing, and final approval. ZAM contributed in idea, concept, data interpretation, manuscript writing, critical reviewing, and final approval. Coronavirus Disease (COVID-19) -events as they happen COVID 19 dashboard: Saudi Arabia for Disease Prevention and Control. Information about Coronavirus Disease Covid-19 Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia Incidence of thrombotic complications in critically ill ICU patients with COVID-19 Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy Clinical characteristics of coronavirus disease 2019 in China Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese center for disease control and prevention Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study Thrombotic and hemorrhagic events in critically ill COVID-19 patients: a French monocenter retrospective study The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings Coagulopathy and antiphospholipid antibodies in patients with Covid-19 Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis COVID-19 patients' clinical characteristics, discharge rate, and fatality rate of meta-analysis Prevalence, severity and mortality associated with COPD and smoking in patients with COVID-19: a rapid systematic review and meta-analysis Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia -a systematic review, meta-analysis, and meta-regression Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan Analysis of mortality in patients with COVID-19: clinical and laboratory parameters. Version 2. Open Forum Neutrophilto-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19 Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China Covid-19 in critically ill patients in the Seattle Region -case series D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19 Thrombocytopenia and its association with mortality in patients with COVID-19 Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China Association between hypoxemia and mortality in patients with COVID-19 Severe obesity, increasing age and male sex are independently associated with worse in-hospital outcomes, and higher in-hospital mortality Kidney disease is associated with in-hospital death of patients with COVID-19 Risk factors for mortality in 244 older adults with COVID-19 in Wuhan, China: a retrospective study Clinical characteristics and outcomes of hospitalised patients with COVID-19 treated in Hubei (epicentre) and outside Hubei (non-epicentre): a nationwide analysis of China Coronavirus disease 19 infection does not result in acute kidney injury: an analysis of 116 hospitalized patients from Wuhan, China Risk factors associated with clinical outcomes in 323 coronavirus disease 2019 (COVID-19) hospitalized patients in Wuhan, China Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study Early predictors of clinical outcomes of COVID-19 outbreak in Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study Clinical course and predictors of 60-day mortality in 239 critically ill patients with COVID-19: a multicenter retrospective study from Wuhan World Health Organization. Laboratory assessment tool for laboratories implementing COVID-19 virus testing Improved molecular diagnosis of COVID-19 by the novel, highly sensitive and specific COVID-19-RdRp/Hel real-time reverse transcription-PCR Assay validated in vitro and with clinical specimens Acute kidney injury in the intensive care unit according to RIFLE Kidney disease: improving global outcomes (KDIGO) chronic kidney disease-mineral and bone disorder (CKD-MBD) Guideline update implementation: Asia Summit Conference Report The role of ECMO in COVID-19: can it provide rescue therapy in those who are critically ill? Therapeutic plasma exchange in adult critically ill patients with life-threatening SARS-CoV-2 disease: a pilot study A pilot study of therapeutic plasma exchange for serious SARS CoV-2 disease (COVID-19): a structured summary of a randomized controlled trial study protocol. Version 2 Coronavirus diseases 19 (COVID-19) guidelines (revised version 1.7). 2020 Association of treatment dose anticoagulation with in-Hospital survival among hospitalized patients with COVID-19 ISTH interim guidance on recognition and management of coagulopathy in COVID-19 Endothelial cell infection and endotheliitis in COVID-19 Lung injury in COVID-19-an emerging hypothesis SARS-CoV-2 and stroke in a New York Healthcare System Clinico-demographic profile & hospital outcomes of COVID-19 patients admitted at a tertiary care centre in north India Clinical characteristics and predictors of outcomes of hospitalized patients with COVID-19 in a multi-ethnic London NHS Trust: a retrospective cohort study COVID-19 and ABO blood group: another viewpoint The effects of blood group types on the risk of COVID-19 infection and its clinical outcome Testing the association between blood type and COVID-19 infection, intubation, and death Clinical characteristics and outcome of hospitalized COVID-19 patients in a MERS-CoV endemic area Smoking, ACE-2 and COVID-19: ongoing controversies Tobacco smoking and COVID-19 pandemic: old and new issues. A summary of the evidence from the scientific literature COVID-19 and smoking: is nicotine the hidden link? Tobacco smoking and COVID-19 infection The impact of COPD and smoking history on the severity of COVID-19: a systemic review and meta-analysis